Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03026569
Other study ID # SaoPSU11
Secondary ID
Status Completed
Phase N/A
First received January 17, 2017
Last updated January 20, 2017
Start date May 2012
Est. completion date September 2012

Study information

Verified date January 2017
Source São Paulo State University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aimed to verify whether orange juice, source of citrus flavonoids and vitamin C, may contribute to the treatment of patients with chronic hepatitis C.


Description:

Forty-three patients with chronic hepatitis C who were being treated with pegylated interferon combined with ribavirin, according to the Clinical Protocol and Therapeutic Guidelines for Viral Hepatitis C and Co-infections of the Brazilian Health Ministry were randomly divided into two parallel groups: (1) orange juice (n = 23), which were supplemented with orange juice (500 mL/d) for 8 weeks; (2) control group (n = 20) composed of patients that were not drinking orange juice regularly. The recruitment process began in February 2012, the intervention was carried out from May 2012 to July 2012, and the data analysis started in September 2012. The sample number took into account variances on total cholesterol with a type I error α = 0.05 and a type II error β = 0.2 (80% power) (Dourado et al., 2015). The minimum sample size should have 20 individuals per group (n = 40), considering an approximately 15% dropout rate. Primary and secondary endpoints were the reduction of total cholesterol and modification of biochemical markers, respectively. Kolmogorov Smirnov and Levene test assessed normality and homogeneity of data, respectively. Assessment of the data was performed in all participants on the first and last day of the experiment. All the parameters were compared between the juice group and the control group using General Linear Model of Repeated Measures Analysis. Differences in baseline patients' characteristics between the two groups were analyzed by One-way analysis of variance (ANOVA). The LSD signed rank post-test was used to assess significant changes in parameters after the start of treatment in each group, and the differences were considered statistically significant at p < 0.05.


Recruitment information / eligibility

Status Completed
Enrollment 43
Est. completion date September 2012
Est. primary completion date July 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Detection of circulating HCV RNA

- Negative HBV surface antigen

- Negative antibodies to HIV

Exclusion Criteria:

- Co-infection with hepatitis B virus (HBV)

- Co-infection with hepatitis A virus (HAV)

- Co-infection with human immunodeficiency virus (HIV)

- Presence of diabetes mellitus,

- Presence of ascites

- Elevation in serum ferritin levels

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Orange juice (500 mL/d)
The patients were instructed to drink orange juice in two daily portions during eight consecutive weeks. Patients from both groups were asked to maintain their usual lifestyle, diet, and physical activity, and they were checked weekly by the researcher's team. Assessments of anthropometric data, dietary intake, as well as blood sample collection for biochemical analysis were performed in all participants on the first and last day of the experiment.

Locations

Country Name City State
Brazil Sao Paulo State University "Julio de Mesquita Filho" Araraquara Sao Paulo

Sponsors (1)

Lead Sponsor Collaborator
São Paulo State University

Country where clinical trial is conducted

Brazil, 

References & Publications (1)

Dourado GK, Cesar TB. Investigation of cytokines, oxidative stress, metabolic, and inflammatory biomarkers after orange juice consumption by normal and overweight subjects. Food Nutr Res. 2015 Oct 20;59:28147. doi: 10.3402/fnr.v59.28147. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Total cholesterol 8 weeks
Secondary Body mass 8 weeks
Secondary Body mass index 8 weeks
Secondary % body fat 8 weeks
Secondary Waist circumference 8 weeks
Secondary Glucose 8 weeks
Secondary Insulin 8 weeks
Secondary HOMA-IR 8 weeks
Secondary LDL-C 8 weeks
Secondary HDL-C 8 weeks
Secondary Triglycerides 8 weeks
Secondary CRP 8 weeks
Secondary alkaline phosphatase 8 weeks
Secondary AST 8 weeks
Secondary ALT 8 weeks
Secondary gamma-GT 8 weeks
Secondary TBARS 8 weeks
Secondary ABTS 8 weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03684915 - Clinical Post-operative Assessment of Chronic Signs & Symptoms Related to Infected Primary Molars After Using Rotary Versus Manual Systems in Cleaning the Root Canals N/A
Completed NCT01788371 - Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus Phase 4
Completed NCT01488526 - Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus Phase 4
Recruiting NCT03476083 - Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine for Preventing Hepatitis B Vertical Transmission Phase 4
Completed NCT02961829 - Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure N/A